Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 13 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LMN-Cdiff01 (Primary)
Indications Clostridium difficile infections
Focus Registrational; Therapeutic Use
Acronyms REPREVE Trial
Sponsors Lumen Bioscience

Most Recent Events

10 Feb 2026 Planned End Date changed from 1 Apr 2026 to 1 Dec 2027.
10 Feb 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Jun 2027.
03 Apr 2025 According to a Lumen Bioscience media release, A manuscript for peer-reviewed publication is in preparation, to include results of the sentinel cohort of this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com